Stock CLN CELON PHARMA S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Company Celon Pharma S.A.

Equities

CLN

PLCLNPH00015

Pharmaceuticals

Market Closed - Warsaw S.E.
Other stock markets
 11:55:43 2024-04-26 am EDT 		5-day change 1st Jan Change
15.24 PLN +1.87% Intraday chart for Celon Pharma S.A. +3.11% -1.42%
Apr. 24 Celon Pharma S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Celon Pharma S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Business Summary

Celon Pharma SA is a Poland-based company primarily engaged in the pharmaceuticals manufacture. The Company focuses on research, development and production of generic drugs for cancer, neurological diseases, diabetes and other metabolic disorders treatment, among others. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir and Valzek, as well as inhalation powder, such as Salmex. The Company's research center develops pharmaceuticals within a number of therapeutic areas, including oncology, neurology, as well as inflammatory and metabolic diseases. The Company is a subsidiary of Glatton sp z o o.

Number of employees: 513

Sales per Business

PLN in Million2021Weight2022Weight Delta
Generic Drugs
83.6 %
173 86.7 % 163 83.6 % -5.77%
Innovative
16.4 %
27 13.3 % 32 16.4 % +20.52%

Sales per region

PLN in Million2021Weight2022Weight Delta
Poland
100.0 %
199 100.0 % 195 100.0 % -2.27%

Managers

Managers TitleAgeSince
Maciej Wieczorek CEO
 Chief Executive Officer - 02-06-19
Malgorzata Siewierska IRC
 Investor Relations Contact - 17-07-31

Members of the board

Members of the board TitleAgeSince
Robert Rzeminski CHM
 Chairman - -
Krzysztof Kaczmarczyk BRD
 Director/Board Member - -
Boguslaw Marek Galewski BRD
 Director/Board Member 62 21-02-15
Urszula Wieczorek BRD
 Director/Board Member - 04-12-31
Artur Wieczorek BRD
 Director/Board Member - 12-12-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 51,056,500 21,028,969 ( 41.19 %) 0 41.19 %

Shareholders

NameEquities%Valuation
Maciej Wieczorek
58.81 %
30,027,531 58.81 % 114 M zł
Generali PTE SA
7.825 %
3,995,257 7.825 % 15 M zł
Vienna PTE SA Vienna Insurance Group
2.544 %
1,298,847 2.544 % 5 M zł
Aviva Investors Poland Towarzystwo Funduszy Inwestycyjnych SA
2.221 %
1,133,870 2.221 % 4 M zł
IPOPEMA TFI SA
1.238 %
632,217 1.238 % 2 M zł
Goldman Sachs Towarzystwo Funduszy Inwestycyjnych SA
1.013 %
517,203 1.013 % 2 M zł
Pekao TFI SA
0.6689 %
341,502 0.6689 % 1 M zł
ESALIENS TFI SA
0.4603 %
235,000 0.4603 % 891 028 zł
Generali Investments TFI SA
0.2920 %
149,074 0.2920 % 565 230 zł
PKO TFI SA
0.2623 %
133,905 0.2623 % 507 716 zł

Company contact information

Celon Pharma SA

ul. Ogrodowa 2A Kielpin

05-092, Lomianki

+48 227 51 59 33

http://www.celonpharma.com
address Celon Pharma S.A.(CLN)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Ratings for Celon Pharma S.A.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
4
Last Close Price
15.24 PLN
Average target price
16.5 PLN
Spread / Average Target
+8.27%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
CELON PHARMA S.A. Stock Celon Pharma S.A.
-1.42% 192M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. CLN Stock
  4. Company Celon Pharma S.A.